TFF Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 03 2024 - 7:00AM
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage
biopharmaceutical company focused on developing and commercializing
innovative drug products based on its patented Thin Film Freezing
(TFF) technology platform, today announced that Dr. Harlan Weisman,
CEO, will present a corporate overview at the H.C. Wainwright 26th
Annual Global Investment Conference. The conference is being held
on September 9 – 11, 2024 at the Lotte New York Palace Hotel.
Presentation Date: |
September 9, 2024 |
Time: |
Available on-demand starting at
7:00 AM Eastern Time |
Webcast
Link: |
https://journey.ct.events/view/2ab5063d-1d8d-4439-8667-a87907f48d97 |
|
|
A webcast of the presentation can be accessed
on the investor relations section of the TFF
Pharmaceuticals website. A replay of the webcast will be archived
and available following the event for approximately 90 days.
https://tffpharma.com/investors/
Dr. Weisman and Kirk Coleman, CFO will be available
for one-on-one meetings throughout the conference. To request a
meeting and to register for the conference, click below:
https://hcwevents.com/annualconference/
ABOUT TFF PHARMACEUTICALS’ THIN FILM
FREEZING (TFF) TECHNOLOGYTFF Pharmaceuticals’ proprietary
Thin Film Freezing (TFF) technology allows for the transformation
of both existing compounds and new chemical entities into dry
powder formulations exhibiting unique characteristics and benefits.
The TFF process is a particle engineering process designed to
generate dry powder particles with advantageous properties for
inhalation, as well as parenteral, nasal, oral, topical and ocular
routes of administration. The process can be used to engineer
powders for direct delivery to the site of need, circumventing
challenges of systemic administration and leading to improved
bioavailability, faster onset of action, and improved safety and
efficacy. The ability to deliver therapies directly to the target
organ, such as the lung, allows TFF powders to be administered at
lower doses compared to oral drugs, reducing unwanted toxicities
and side effects. Laboratory data suggests the aerodynamic
properties of the powders created by TFF can deliver as much as 75%
of the dose to the deep lung. TFF does not introduce heat, shear
stress, or other forces that can damage more complex therapeutic
components, such as fragile biologics, and instead enables the
reformulation of these materials into easily stored and
temperature-stable dry powders, making therapeutics and vaccines
more accessible for distribution worldwide. The advantages of TFF
can be used to enhance traditional delivery or combined to enable
next-generation pharmaceutical products.
ABOUT TFF PHARMACEUTICALSTFF
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
engaging patented rapid freezing technology to develop and
transform medicines into potent dry powder formulations for better
efficacy, safety, and stability. The company’s versatile TFF
technology platform has broad applicability to convert most any
drug, including vaccines, small and large molecules, and biologics,
into an elegant dry powder highly advantageous for inhalation or
for topical delivery to the eyes, nose and skin.
SAFE HARBORThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that could cause actual results to
differ materially, including (i) the risk that further data from
the Company’s ongoing Phase 2 trial of TFF TAC may not be
consistent with the positive preliminary data obtained to date,
(ii) the risk that the Company may not be able to obtain additional
working capital with which to continue its current operations and
clinical trials as and when needed, (iii) success in early phases
of pre-clinical and clinical trials do not ensure later clinical
trials will be successful; (iv) no drug product incorporating the
TFF platform has received FDA pre-market approval or otherwise been
incorporated into a commercial drug product, (v) the Company has no
current agreements or understandings with any large pharmaceutical
companies for the development of a drug product incorporating the
TFF Platform, and (vi) those other risks disclosed in the section
“Risk Factors” included in the Company’s Quarterly Report on Form
10-Q filed with the SEC on August 14, 2024. The
Company cautions readers not to place undue reliance on any
forward-looking statements. The Company does not undertake and
specifically disclaims any obligation to update or revise such
statements to reflect new circumstances or unanticipated events as
they occur, except as required by law.
Investor Relations Contact:Jason
NelsonCoreIRjason@coreir.com
TFF Pharmaceuticals (NASDAQ:TFFP)
Historical Stock Chart
From Nov 2024 to Dec 2024
TFF Pharmaceuticals (NASDAQ:TFFP)
Historical Stock Chart
From Dec 2023 to Dec 2024